PT - JOURNAL ARTICLE AU - Crawford, Forrest W. AU - Jones, Sydney A. AU - Cartter, Matthew AU - Dean, Samantha G. AU - Warren, Joshua L. AU - Li, Zehang Richard AU - Barbieri, Jacqueline AU - Campbell, Jared AU - Kenney, Patrick AU - Valleau, Thomas AU - Morozova, Olga TI - Impact of close interpersonal contact on COVID-19 incidence: evidence from one year of mobile device data AID - 10.1101/2021.03.10.21253282 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.10.21253282 4099 - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253282.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253282.full AB - Close contact between people is the primary route for transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). We sought to quantify interpersonal contact at the population-level by using anonymized mobile device geolocation data. We computed the frequency of contact (within six feet) between people in Connecticut during February 2020 – January 2021. Then we aggregated counts of contact events by area of residence to obtain an estimate of the total intensity of interpersonal contact experienced by residents of each town for each day. When incorporated into a susceptible-exposed-infective-removed (SEIR) model of COVID-19 transmission, the contact rate accurately predicted COVID-19 cases in Connecticut towns during the timespan. The pattern of contact rate in Connecticut explains the large initial wave of infections during March–April, the subsequent drop in cases during June–August, local outbreaks during August–September, broad statewide resurgence during September–December, and decline in January 2021. Contact rate data can help guide public health messaging campaigns to encourage social distancing and in the allocation of testing resources to detect or prevent emerging local outbreaks more quickly than traditional case investigation.One sentence summary Close interpersonal contact measured using mobile device location data explains dynamics of COVID-19 transmission in Connecticut during the first year of the pandemic.Competing Interest StatementThis work was supported by NIH grants NICHD 1DP2HD091799-01, NIAID R01AI137093-03, Cooperative Agreement 6NU50CK000524-01 from the Centers for Disease Control and Prevention, funds from the COVID-19 Paycheck Protection Program and Health Care Enhancement Act, and the Pershing Square Foundation. Computing resources at Stony Brook University were funded by National Science Foundation grant #1531492. Forrest W. Crawford is a paid consultant to Whitespace Solutions, Ltd. Jacqueline Barbieri, Jared Campbell, Patrick Kenney, and Thomas Valleau, are employees of Whitespace Solutions, Ltd.Funding StatementThis work was supported by NIH grants NICHD 1DP2HD091799-01, NIAID R01AI137093-03, Cooperative Agreement 6NU50CK000524-01 from the Centers for Disease Control and Prevention, funds from the COVID-19 Paycheck Protection Program and Health Care Enhancement Act, and the Pershing Square Foundation. Computing resources at Stony Brook University were funded by National Science Foundation grant # 1531492.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Yale University institutional review board. This work was also reviewed by CDC and was conducted consistently with applicable federal law and CDC policy.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data required to reproduce the analysis are available from the authors.